{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009249","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.362878+00:00","generated_at":"2026-05-22T04:52:10.886900+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline","bullets":["Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.","Net loss of $7.5M ($0.24 loss per share) compared to net loss of $9.3M ($0.31 per share) in Q1 2024.","Operating loss improved to $8.6M from $10.3M YoY; operating expenses decreased 18.2%.","Cash and marketable securities totaled $21.5M as of March 31, 2025.","On track to begin clinical evaluations for 4 tests and complete India manufacturing facility by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009249","json":"https://secwatch.observer/filing/0001641172-25-009249.json","markdown":"https://secwatch.observer/filing/0001641172-25-009249.md","text":"https://secwatch.observer/filing/0001641172-25-009249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/0001641172-25-009249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:52:10.886900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}